Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0634 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MK-0634 50 mg | EXPERIMENTAL | All participants will receive placebo for the 1 week prior to randomization |
| MK-0634 125 mg | EXPERIMENTAL | All participants will receive placebo for the 1 week prior to randomization |
| MK-0634 375 mg | EXPERIMENTAL | All participants will receive placebo for the 1 week prior to randomization |
| Placebo | PLACEBO_COMPARATOR | All participants will receive placebo for the 1 week prior to randomization |
| Name | Type | Description |
|---|---|---|
| MK-0634 50 mg | DRUG | one capsule orally, once daily in morning |
| MK-0634 125 mg | DRUG | one or three capsules orally, once daily in morning |
| Placebo for MK-0634 | DRUG | one, two, three or four capsules orally once daily in morning |
Inclusion Criteria: * Postmenopausal females (ages 40-74) with predominantly urge urinary incontinence overactive bladder episodes. * Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards. Exclusion Criteria: * Patients must ...
MK-0634 is an investigational small molecule developed by Merck & Company, Inc. (ticker MRK) for urinary incontinence. It has been studied in a Phase 2 clinical trial in patients with overactive bladder. MK-0634 is also known as MK-0634 50 mg.
MK-0634 is being studied for urinary incontinence, specifically in patients with overactive bladder. The Phase 2 trial enrolled women aged 40 years and older with this condition. It is an investigational therapy and has not been approved for commercial use.
MK-0634 is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the Phase 2 clinical program evaluating the drug in urinary incontinence.
MK-0634 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The completed study was a randomized, double-blind, placebo-controlled trial in patients with overactive bladder.
MK-0634 has been evaluated in one completed Phase 2 trial, NCT00231790, titled A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007). The trial enrolled 848 participants, was randomized, double-blind, and placebo-controlled, and studied women aged 40 years and older with urinary incontinence.